Clinical Experience with 0.05% Halometasone/1% Triclosan Cream in the Treatment of Acute Infected and Infection-Prone Eczema in Egypt

Abstract

This is a report of a non-comparative trial to assess the usefulness of a 0.05% halometasone and 1% triclosan combination in a cream base in the treatment of acute infected and infection-prone eczematous skin disorders. The trial was carried out in three centres. Of the 126 patients admitted to the trial, 25 were lost to follow-up. The remaining 101 patients utilized the cream as the only treatment during the 3-week duration of therapy. Medication was applied to the lesions twice daily without occlusive dressing. The cream gave either excellent or good results in 89% of cases. Infection, which was initially present in 38 cases, disappeared within 5 days from 27 (71%) of them and within 6-10 days from a further six (16%) cases. The therapeutic effect was first noted (in 43 cases) within a mean of 2.7 days (+/- 1.01). The cream did not give rise to any serious local unwanted effects. Systemic unwanted effects were suspected in an 8-month old infant with extensive atopic dermatitis. The findings in this study substantiate those of other investigators that this halometasone/triclosan preparation combines potent and rapid therapeutic effect with excellent local and systemic tolerability.

Evaluation of efficacy, safety, and tolerability of fixed dose combination (FDC) of halometasone 0.05% and fusidic acid 2% w/w topical cream versus FDC of betamethasone valerate 0.12% and neomycin sulphate 0.5% w/w topical cream in the treatment of infected eczematous dermatosis in Indian subjects: A randomized open-label comparative phase III multi-centric trial

“…Earlier studies have shown that combination of halometasone and antibacterial agents/fusidic acid is safe and effective in the treatment of eczema. [11-12] Studies have shown that combination of halometasone and fusidic acid is safe and effective[19] and our study confirms this in Indian population. This FDC was well tolerated among our patients, as only one AE was reported in the group A.…”

“…[9] Treatment with halometasone and antibacterial agent (triclosan) was found to be superior with higher success and cure rate along with good safety profile; an early cure (in less than 20 days) compared to other steroid and antibiotic combination. [10–12] Safety, efficacy, and tolerability of Halometasone in Indian patients with acute and chronic eczema have been documented. [13]…”